Terminated PHASE2 INTERVENTIONAL 2-arm NCT04891185

Visualisation of Indocyanine Green in Primary and Interval Debulking for Ovarian Cancer (VIPIDO)

Sponsor: Universitaire Ziekenhuizen KU Leuven

Updated 7 times since 2021 Last updated: Oct 2, 2023 Started: Oct 1, 2021 Primary completion: Oct 1, 2023 Completion: Oct 1, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Clinical futility

Other terminated trials from Universitaire Ziekenhuizen KU Leuven

See all terminations from Universitaire Ziekenhuizen KU Leuven

Other Ovarian Cancer trials with similar outcome

Browse all Ovarian Cancer trials

This PHASE2 trial investigates Ovarian Cancer and is currently terminated or withdrawn. Universitaire Ziekenhuizen KU Leuven leads this study, which shows 7 recorded versions since 2021 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Nov 2023 — Jul 2024 [monthly]

Terminated PHASE2

Status: Enrolling By Invitation → Terminated
Jun 2023 — Nov 2023 [monthly]

Enrolling By Invitation PHASE2
Nov 2022 — Jun 2023 [monthly]

Enrolling By Invitation PHASE2

▶ Show 2 earlier versions

Dec 2021 — Nov 2022 [monthly]

Enrolling By Invitation PHASE2

Status: Not Yet Recruiting → Enrolling By Invitation
Jun 2021 — Dec 2021 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Universitaire Ziekenhuizen KU Leuven

Data source: Universitaire Ziekenhuizen KU Leuven

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Leuven, Belgium